																											1= old CDF+D 2=new CDF d
ъg	Indication (from CDF list)	Licenced for this indicatior (according to the European Medicines Agency) (YIN/?)	Available to patients from (CDF)	old CDF drug remaining on new CDF list 18m (Y, YB=yes but has been reviewed, Not applicable because new drug)	Listed after 1/1/18	arrangement and	Technology appraisal status None (N), Underway (U), Complete (C), abandoned (A), ???	NICE TA number or link to incomplete TA	Date of TA publication or expected date	Date on managed access agreement	Number of redacted areas (in addition to the commercial arrangement)	Text surrounding redaction	Description of clinical uncertainty in MAA - P, I, C, O, £		Which study is anticipated to drive decision making next time the drug is appraised? (SACT (S), Trial (T), other (O))		registration of the SACT study, link or mention of a protocol?	SACT	SACT data expected	clinical trial requested/ ongoing	name	Trial on registry Y/N/?	outcome of prime interest to the NICE committee	other outcomes of interest	when are data expected?	other study mentioned/req uested	2=new CDF di 3=old awaitin, 4=old not fori 5=new CDF ni 6=after 1/1/18 commissionir 7= old, no NIC entering commissionir seen by NICE commissionir after 1/1/18 e routine comm noNICE (typic label")
ctinib	Untreated anaplastic lymphoma kinase- positive advanced nonsmall-cell lung cancer	v	28/6/18	N	v		c	TA536	8/8/1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
201110	Newly diagnosed low to intermediate risk						0				101					101		100	1075	104	101			103			
nic trioxid	acute promyelocytic leukaemia in CHILDREN	N	4/6/18	N	Y	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
nic trioxid	Relapsed/refractory acute promyelocytic		4/6/18		~			NA	NA					NA							NA	NA	NA			NA	
ic trioxid	 leukaemia in CHILDREN Newly diagnosed low to intermediate risk 	N	4/6/18	N	Y	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
ic trioxid	acute promyelocytic leukaemia in ADULTS	Y	4/6/18	N	Y	N	С	TA526	13/6/1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
c trioxid	Relapsed/refractory acute promyelocytic		4/6/18						13/6/1		NA	NA			NA	NA			NA	NA		NA	NA		NA	NA	
	e leukaemia in ADULTS Relapsed low grade lymphoma	Y possibly	4/6/18		N - but entering	N	C	TA526 NA	13/6/1	NA	NA	NA	NA NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA			NA	
mustine	Relapsed multiple myeloma	possibly	29/7/16		N - but entering		N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	
izumab	Third line for low grade gliomas of childhood		29/7/16		N	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	
	First line for recurrent or metastatic cervical																										
izumab	cancer in combination with chemotherapy	Y	29/7/16	Y	N	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
izumab	First line for advanced epithelial ovarian, fallopian tube, or primary peritoneal cance	v	29/7/16	v	N	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
tzumab	Bortezomib naive relapsed multiple myeloma	· Y	29/7/16		N	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	
0.110	Brentuximab-naïve relapsed/refractory Hodgkin lymphoma following at least 2 prior therapies wheneutologous stem cell		20//10					.wt	t	rert					t		- in the second se	- wh	1975					reri		105	
imab	transplant or multiagent chemotherapy is not a treatment option in CHILD patient Brentuximab-naïve relapsed/refractory Hodgkin lymphoma following at least 2 prior therapies when autologous stem cell	?	29/7/16	YB	N - but entering	N	N	NA	NA	28/4/1	7) NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
kimab	transplant or multiagent chemotherapy is not a treatment option in ADULT patients	Y	29/7/16	YB	N - but entering	N	с	TA524	28/6/1	28/4/1	7	NA	o	the proportion o	rs	Y	retrospective an	astem cell transpl	٤ Nov 201	7 Y	supported by th	e ?	?	?	Nov 2017	Comparrison in	s
antinib	Treatment-naïve intermediate or poor risk advanced renal cell carcinoma	Y	24/8/18	N	Y	N	с	TA463	9/8/1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	NA	NA	
antinib	First line for medullary thyroid cancer	Y	29/7/16		N	N	A	TA516	March 2		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA			NA	
	Relapsed/refractory acute myeloblastic																										
ine	leukaemia	N	29/7/16	Y	N	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
ine	Relapsed/refractory acute lymphoblastic leukaemia	Y	29/7/16	YB	N	N	A	https://www.nice	. 1/12/1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
	As part of 1st line therapy for high risk neuroblastoma in patients aged 12 months and above and who have both responded to induction chemotherapy and been treated with myeloablative therapy and stem cell																										
	et transplantation RELAPSED or REFRACTORY neuroblastoma in patients aged 12 months and above and who have then both responded to intensive induction chemotherapy used to treat high risk 1st line patients and been treated with myeloablative et therapy and stem cell transplantation	Y	22/8/18		Y	N	с	TA538 TA538	22/8/11		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	
ab oz	Treatment of relapsed/refractory Philadelphia positive and negative B cell precursor acute of lymphoblastic leukaemia in CHILD patients	N	9/8/18	N	Y	N	U	possible GID-TA	19/8/18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
	Relapsed/refractory Philadelphia positive and Philadelphia negative B cell precursor acute																										
ab oz	Philadelphia negative B cell precursor acute of lymphoblastic leukaemia in ADULT patients	Y	9/8/18	N	Y	N	U	GID-TA10091	19/9/1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
ь	Differentiated thyroid cancer after radioactive iodine	Y	15/2/18	N	Y	N	c	TA535	8/8/1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
	Unresectable or metastatic, progressive, well differentiated and comptostatio recentor						-																				
	positive gastroenteropanceatic tri neuroendocrine carcinoma FLT3 mutation positive acute myeloid	Y	20/7/18		Y	N	с	TA539	29/8/1		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
in	leukaemia in adults Refractory T-cell acute lymphoblastic leukaemia or refractory T-cell lymphoblastic	Y	4/6/18	N	Y	N	С	TA523	13/6/1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
ne	non-Hodgkin's lymphoma In combination with doxorubicin for the treatment of advanced soft tissue sarcoma in	N	29/7/16	YB	N	N	A	https://www.nice	27/12/1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
ab	PAEDIATRIC patients	N	9/6/17	N	N	N	?	?	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
b	negative, locally advanced or metastatic breast cancer	Y	16/11/17	N	N	N	С	TA495	20/12/1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	?	?	?	?	?	?	?	
Lipo	Sarcoma (seems to be for those with cardiac st problems)	N	29/7/16	Y	N	N	N	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	
uma	Relapsed or refractory classical Hodgkin lymphoma in CHILDREN who are stem cell transplant-ineligible and have failed b brentuximab vedotin	N	25/7/18	N	Y	N	?	?	?	?	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	
ab	First line treatment of locally advanced or metastatic breast cancer	HER2 only	29/7/16	Y	N	N	N	?	?	?	?	?	?	?	?	2	2	2	?	?	?	?	?	?	?	?	
	Differentiated thyroid cancer after radioactive							TA535																			
	iodine First line treatment of medullary thyroid cancer	r v	29/7/16		N	N	N		8/8/1		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	
	Locally advanced or metastatic urothelial cancer in patients who are ineligible for				N			https://www.nice				It was originally	e			NPA	N/A	NA				14/4					
nab	cisplatin based chemotherapy 1st or subsequent line systemic therapy for ROS1-positive inoperable locally advanced/metastatic non squamous nonsmal	r I	1/11/17	ni	N	T	c	TA492	6/12/1			3 in the trial proto		OS and PFS co		r	N	OS, duration of t			IMvigor 130	ſ	OS, PFS, treatn		Dec 2020	Clinical trial Ox	2
	cell lung cancer	Y	31/6/18	N	Y	Y	С	<u>TA529</u>	4/7/1	July 201	8 :	2 dates when trial	ls C, O	Lack of compara	al S	Y	Y		k 2023 (driven by	aY	PROFILE 1001	('Y	OS	Objective respon	April 2023	Asian patients (r	1
imab	Relapsed and refractory multiple myeloma	Y	17/1/18	N	Y	Y	с	TA510	14/3/1	March 201	8 0	NA	0	Os in a UK popu	IS	Y	N	baseline charact data	?	NA	NA	NA	NA	NA	Зу	NA	
	Waldenstrom's Macroglobulinaemia	Y	18/9/17	N	N	Y	С	TA491	22/11/1	sept 17		NA	0	pre-progression	IS	Y	N	Pre-progressi	01/11/2019-20	Y	phase 2 registra	ati Y - https://dinic	al OS	longer term surv	Aug 2018	isease-specific \	
(with	le Relapsed or refractory multiple myeloma Maintenance for relapsed, platinum-sensitive and high grade serous ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based SECOND		19/12/17	N	N	Y	С	<u>TA505</u>	7/2/1	Nov 1	7	D NA	0	magnitude of th	έT	Y		OS. Duration of	t Dec 1	Ŷ	Phase III TOUR	NΥ	progression-free	e OS and OS in pa	Dec 2019	Data from UK N	a
ib	response following platinum-based SECOND line chemotherapy and who HAVE a germline BRCA mutation	Y	1/6/18	N	N	Y	с	TA523	4/7/1	NA		D NA	o	mature OS data	, т	Y	N	overall survival,	c as trial	Y	pivotal ENGOT-	ĊY	Mature OS	PFS, QOL, time	June 2020	NA	

Drug	Indication (from CDF list)	Licenced for this indication (according to the European Medicines Agency) (YNN7)	Available to patients from (CDF)	old CDF drug remaining on new CDF list 18m (Y, YB=yes but has been reviewed, Not applicable because new drug)	Listed after 1/1/18	Managed Access Agreement (data collection arrangement and commercial arrangement)	(C), abandoned	NICE TA number or link to incomplete TA	Date of TA publication or expected date	Date on managed access	commercial	Text surrounding redaction	Description of clinical uncertainty in MAA - P, I, C, O, E	Detail of	Which study is anticipated to drive decision making next time the drug is appraised? (SACT (S), Trial (T), other (O)	SACT study requested	registration of the SACT study, link or mention of a protocol?		SACT data expected	clinical trial requested/ ongoing	name	Trial on registry Y/N/?	outcome of prime interest to the NICE committee	outcomes of	when are data	other study mentioned/req	1e old CDF+DCA, 2mev CDF drug+DCA, 3vold availing NICE, 3vold availing NICE, 5vnew CDF no NICE, 5vnew CDF no NICE, 5vafter 1/1/18 entering commissioning, 4va NICE rold, no NICE and entering commissioning, 9va difference after 1/1/18 entering noNICE (typically "off label")
Niraparib	Maintenance for relapsed, platinum-sensitive and high grade serous ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based SECOND OR LATER line chemotherapy and who DO NOT HAVE a germline BRCA mutation	Y	1/6/1	8 N	N	Y	с	TA523	4/7/18	NA	o	NA	0	mature OS data,	т	Y	N	overall survival, o	as trial	Y	pivotal ENGOT-	CY	Mature OS	PFS, QOL, time I	June 2020	NA	:
Nivolumab	Previously treated locally advanced or metastatic non-squamous non-small cell lung cancer	Y	20/9/1	7 N	N	Y	с	<u>TA484</u>	1/11/17	20/9/17		NA	P, 0	nivolumab has a	т	Y	N	overall survival, o	June 201	9 Y	CheckMate 057	·Υ	os	ORR, PFS, PDL1	June 2019	Phase Ilb. 7-yea	
Nivolumab	Previously treated locally advanced or metastatic squamous non-small cell lung cancer	Y	20/9/1	7 N	N	Y		TA483	1/11/17				P, 0	Awaiting results	т	Y	N	overall survival, o	June 201	9 Y	CheckMate 017		os	ORR, PFS, PD-L		A 7-year data cu	
	Recurrent or metastatic squamous-cell carcinoma of the head and neck after							TA490						_								-					
	platinum-based chemotherapy Follicular lymphoma refractory to rituximab	Y Y	27/7/1		N	v	c	TA490	30/8/17			NA xxxxxxxxxx, Head occur is by mid-x		plausible that niv		Y Y	N	OS, duration, PD length of treatme clinical practice		Y Y	CheckMate-141	-	Overall survival uncertainty aro			N	
	In combination with doxorubicin for the treatment of advanced soft tissue sarcoma in ADULT patients	v	9/6/1		N	~	c	TA465	9/8/17			name of Eli-Lily		clinical uncertain		•	N	further informatio			ANNOUNCE JO			L, length of follow-			
	Locally advanced or metastatic epidermal growth factor receptor and T790M mutation- positive non-small-cell lung cancer (NSCLC)	Y	4/10/1		N	Ŷ	c	TA416	26/10/16			REdactions in ta		Extrapolation of		Y Y	N	duration of treatm			AURA3 and AU	-		ility to UK populati		AURA2 clintrials	
	Relapsed or refractory classical Hodgkin lymphoma in ADULTS who are stem cell transplant-ineligible and have failed brentuximab vedotin	Y	25/7/1	8 N	N	Y	с	TA540		Sept 2018	3	The expected m	1, 0	UK oractice diffe		Y	N	overall survival, o	?	Y	KEYNOTE-087	ĸ	os	transplant	July 2022		
	Untreated PD-L1 positive metastatic non- small-cell lung cancer	Y		N	N	Y	с	TA447		31/6/17			0	overall survival b	т	Y	N	Data on time on		Y	KEYNOTE-024			when 170 death ev			
Pembrolizumab	Locally advanced or metastatic urothelial cancer previously treated with platinum- based chemotherapy	Y	16/3/1	8 N	N	Y	с	TA519	28/4/18	April 2018	0	NA	0	long-term OS be	т	Y	N	overall survival. t	?	Y	KEYNOTE-045	Y	OS. Specifically	, none mentioned	Dec 2018	N	
	First line treatment of locally advanced or metastatic urothelial cancer in patients who are ineligible for cisplatin-based	Y	27/4/1		N	Y	v	TA522	13/6/18				0	ong-term OS ber		Y	N	overall survival a		Y	KEYNOTE-045			u none mentioned			
	Chronic lymphatic leukaemia in the ABSENCE of 17p deletion (and absence of TP53 mutation if tested)	v	5/10/1		N	~	c	TA48Z	8/11/17				C, O	Venetoclax overa		~	N	use of BSC after		O NA	NA	NA	NA			NA	
	Chronic lymphatic leukaemia in the PRESENCE of 17p	γ	5/10/1		N	Y	c	TA487	8/11/17				c,o	Venetoclax overa		Y	N	time on treatmen noted that charac			NA	NA	NA	NA		NA	